Join Growin Stock Community!

Intuitive surgical inc(ISRG.US AI Earnings Summary)

US StockHealthcare
No presentation for ISRG

ISRG AI Earnings Summary (In-Depth)

Last updated: 2026-10-20 (US time)

2026 Q3

Core Highlights

  • Stock Price Reaction: INTUITIVE SURGICAL INC reported strong earnings after the U.S. market close on October 20, 2026. Impacted by a $450M settlement and future instrument price reductions, on the first trading day after earnings, 10/21, the stock closed at $428.12, down 2.26% from the 10/20 close of $438.00. Even though revenue and earnings both exceeded market expectations, management's disclosure of the settlement agreement and the estimated 3% to 5% decline in revenue per procedure from instruments and accessories (I&A) triggered market concerns over long-term margins.
  • Against Market Expectations: INTUITIVE SURGICAL INC's Non-GAAP EPS this quarter was $3.00, significantly exceeding the $2.65 TradingView pre-earnings market expectation by approximately 13.2%; revenue of $3.049B was about 4.8% above the $2.91B market expectation. The significant beat in EPS was primarily driven by a better product mix (with the higher-priced da Vinci 5 and SP systems accounting for approximately 65% of total shipments), continued growth in I&A revenue, and the recognition of a one-time $28M tariff refund benefit.
  • Against Own Previous Guidance: All financial data this quarter exceeded or met the company's own expectations from the previous quarter. Non-GAAP gross margin reached 69.9%, surpassing the upper end of the previous guidance range of 68% to 69% by approximately 0.9 percentage points; the 2026 full-year procedure growth guidance range was also narrowed and the lower end raised to 14% to 15%.
  • In One Sentence: INTUITIVE SURGICAL INC demonstrated resilient operational momentum, with da Vinci 5 and SP platform penetration driving an earnings beat, though the settlement and future I&A price cuts sparked margin concerns, and the stock closed down 2.26% on the first trading day after earnings.

Quarterly Highlights

Non-GAAP EPS significantly beat market expectations, with a surge in the systems business driving overall outperformance.

  1. Significant Non-GAAP EPS Beat: Non-GAAP EPS for the quarter was $3.00, approximately 13.2% higher than the $2.65 TradingView pre-earnings market expectation, representing a 25% year-over-year increase. The primary contributors to the beat were systems revenue growing 30% year-over-year to $769M and a Non-GAAP gross margin of 69.9%, both significantly better than the company's own upper-end guidance.

  2. Total Revenue Up 22% YoY, Accelerated Across Three Main Business Lines: Total revenue for the quarter slightly exceeded $3B. Within this, Instruments & Accessories (I&A) grew 18% YoY to $1.8B, Systems grew 30% YoY to $769M, and Services grew 22% YoY to $482M. Total recurring revenue (I&A plus Services) accounted for 84% of total revenue, reflecting high stability in the subscription-based business model.

  3. Record da Vinci System Shipments, da Vinci 5 and SP Account for 65% of Global Shipments: Global shipments totaled 546 da Vinci systems this quarter, up 28% YoY. This included 315 da Vinci 5 units and 42 SP units (a single-quarter record). The global installed base of da Vinci 5 systems has surpassed 2,000 units, with over 18,000 surgeons trained, indicating continued penetration of the next-generation platform.

  4. International Procedure Volume Up 20% YoY, Accelerated Penetration of Benign Procedures Overseas: da Vinci procedure volume outside the US grew 20% YoY, with Europe up 20%, Asia up 19%, and other markets up 22%. Overseas benign procedure volume grew 41% YoY (compared to 37% in Q2 and 34% in Q1), now accounting for over a quarter of international volume, showing that ISRG's expansion into non-urologic oncology fields is accelerating.

  5. Non-GAAP Gross Margin at 69.9%, 0.9 Percentage Points Above Guidance Ceiling: Non-GAAP gross margin was 69.9% this quarter, approximately 0.9 percentage points higher than the 69% upper limit of the full-year guidance provided last quarter (includes a $28M one-time tariff refund; excluding this, it was 68.9%, a 90 bps YoY increase). The improvement was mainly driven by lower product costs and fixed-cost leverage.

  6. Ion Platform Procedure Volume Up 31% YoY, Insurance Coverage Secured in South Korea: Ion procedure volume grew 31% YoY this quarter, with the US up 29%. This quarter, the Ion platform secured health insurance reimbursement eligibility in South Korea. Ion systems are now installed in 12 countries outside the US, and a new manufacturing facility in Penang, Malaysia, is expected to start production in 2028, laying the foundation for long-term international expansion.

  7. SP Single-Port Platform Procedure Volume Up 55% YoY, Global Installed Base Up 42% YoY: SP procedure volume grew 55% YoY this quarter, with the US up 50% and South Korea up 40%. The global SP installed base reached 487 units (up 42% YoY). The SP stapler continues to see expanded adoption, and management plans to submit a 510(k) application to the FDA for the SP vessel sealer in Q4, which is expected to further broaden the indications for the SP platform.

  8. Large-Scale Share Repurchase Demonstrates Active Capital Allocation: The company repurchased $2.9B of stock at an average price of $377 per share this quarter, the largest single-quarter repurchase in the company's history. The period-end cash and investment balance was $6.8B. Despite the decrease from the previous quarter's $8.6B balance, management maintains high confidence in long-term growth.

Sign up for free!

You can sign up for free or Log In to read more information!

Free In-Depth for popular US stocks:

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer